S'abonner

Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study - 01/05/25

Doi : 10.1016/S1470-2045(25)00099-3 
Ramaprasad Srinivasan, MD a, Othon Iliopoulos, MD b, Kathryn E Beckermann, MD c, Vivek Narayan, MD d, Benjamin L Maughan, MD e, Stephane Oudard, MD f, Tobias Else, MD g, Jodi K Maranchie, MD h, Ane B Iversen, MD i, Jerry Cornell, PhD j, Rodolfo F Perini, MD j, Yanfang Liu, MD j, W Marston Linehan, MD a, Eric Jonasch, MD k, ⁎
a Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA 
b Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA 
c Vanderbilt University Medical Center, Nashville, TN, USA 
d University of Pennsylvania, Philadelphia, PA, USA 
e University of Utah, Salt Lake City, UT, USA 
f Hôpital Européen Georges Pompidou, University Paris Cité, Paris, France 
g University of Michigan, Ann Arbor, MI, USA 
h University of Pittsburgh, Pittsburgh, PA, USA 
i Aarhus University Hospital, Aarhus, Denmark 
j Merck & Co, Rahway, NJ, USA 
k The University of Texas MD Anderson Cancer Center, Houston, TX, USA 

* Correspondence to: Dr Eric Jonasch, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA The University of Texas MD Anderson Cancer Center Houston TX 77030 USA

Summary

Background

Hypoxia-inducible factor-2α inhibitor belzutifan is approved for von Hippel-Lindau disease-associated renal cell carcinoma, CNS haemangioblastomas, and pancreatic neuroendocrine tumours, based on previously published initial results from the LITESPARK-004 study. Updated results are presented here after a median follow-up of nearly 50 months.

Methods

In this single-arm, phase 2 study, participants were enrolled at 11 centres in Denmark, France, the UK, and the USA. Oral belzutifan 120 mg once daily was given to eligible adults aged 18 years or older with a diagnosis of von Hippel-Lindau disease (based on germline VHL alterations), at least one measurable renal cell carcinoma tumour, no tumour larger than 3 cm that necessitated immediate surgery, no metastatic disease, no previous systemic anticancer treatment, and an Eastern Cooperative Oncology Group performance status score of 0 or 1. The primary endpoint was the proportion of participants with an objective response in von Hippel-Lindau disease-associated renal cell carcinoma per Response Evaluation Criteria in Solid Tumours, version 1.1, determined by an independent review committee, and assessed in all participants who received at least one dose of belzutifan. This ongoing study is no longer recruiting and is registered at ClinicalTrials.gov, NCT03401788.

Findings

Between May 31, 2018, and Mar 29, 2019, 61 participants were enrolled; 36 (59%) were continuing treatment as of April 3, 2023. The median age of all enrolled participants was 41·0 years (IQR 29·0–51·0); 32 (52%) of 61 participants were male and 29 (48%) were female; most were White (n=55; 90%). Median study follow-up was 49·9 months (IQR 48·9–52·2). 41 (67%; 95% CI 54–79) of 61 participants with renal cell carcinoma had an objective response; seven (11%) had a complete response and 34 (56%) a partial response. 13 grade 3 treatment-related adverse events occurred in 11 (18%) participants (anaemia: seven [11%]; fatigue: three [5%]; urinary tract infection: one [2%]; hypoxia: one [2%]; and blister: one [2%]). None of the participants had a grade 4 or 5 treatment-related adverse event. Four (7%) participants had serious treatment-related adverse events (one participant each: anaemia, urinary tract infection, intracranial haemorrhage, and hypoxia).

Interpretation

Updated results support the use of belzutifan as systemic treatment for von Hippel-Lindau disease-associated renal cell carcinoma.

Funding

Merck Sharp & Dohme, a subsidiary of Merck & Co, Rahway, NJ, USA; the Intramural Research Program of the National Institutes of Health, National Cancer Institute Center for Cancer Research; and a grant from the National Cancer Institute.

Le texte complet de cet article est disponible en PDF.

Plan


© 2025  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 26 - N° 5

P. 571-582 - mai 2025 Retour au numéro
Article précédent Article précédent
  • Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial
  • Emil Lou, Modassir S Choudhry, Timothy K Starr, Timothy D Folsom, Jason Bell, Blaine Rathmann, Anthony P DeFeo, Jihyun Kim, Nicholas Slipek, Zhaohui Jin, Darin Sumstad, Christopher A Klebanoff, Katherine Ladner, Akshat Sarkari, R Scott McIvor, Thomas A Murray, Jeffrey S Miller, Madhuri Rao, Eric Jensen, Jacob Ankeny, Mahmoud A Khalifa, Anil Chauhan, Benjamin Spilseth, Ajay Dixit, Paolo P Provenzano, Wenjing Pan, Daniel Weber, Miranda Byrne-Steele, Tom Henley, David H McKenna, Matthew J Johnson, Beau R Webber, Branden S Moriarity
| Article suivant Article suivant
  • Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial
  • Richard J Bryant, Ioana R Marian, Roxanne Williams, J Francisco Lopez, Claudia Mercader, Mutie Raslan, Christopher Berridge, Jessica Whitburn, Teresa Campbell, Steve Tuck, Vicki S Barber, Jessica Scaife, Aimi Hewitt, Amy Taylor, Alexander Ooms, Filipa Landeiro, Matthew Little, Jane Wolstenholme, Sukanya Ghosh, John M Reynard, Freddie C Hamdy, Matthew P C Liew, Tom A Leslie, James W F Catto, Derek J Rosario, Altan Omer, Daniel W Good, Robert HR Gray, Sashi Kommu, Daniel Chung, Hannah Wells, Krishna Narahari, Ruth E Macpherson, Clare Verrill, Ben Eddy, Hide Yamamoto, Alastair D Lamb, TRANSLATE Trial Study Group, Richard J Bryant, Alastair D Lamb, Roxanne Williams, Ioana R Marian, Teresa Campbell, J Francisco Lopez, Claudia Mercader, Mutie Raslan, Ruth E Macpherson, Clare Verrill, Vicki S Barber, Jessica Scaife, Aimi Hewitt, Amy Taylor, Alexander Ooms, Filipa Landeiro, Jane Wolstenholme, Freddie C Hamdy, John M Reynard, Steve Tuck, Silvia Mantovani, Richard Colling, Lisa Browning, Odette Dawkins, Jacob Freda, Nadjat Medeghri, Lucy Davies, Matthew Parkes, James Whiteside, Kelly Rafique, Toni Bassett, Patrick Tan, Mark Sullivan, Jeremy Crew, William Gietzmann, Sarah Howles, Ben Turney, Sarp Keskin, Ibrahim Jour, Simon Brewster, Musaab Yassin, Catherine Hobbs, Aaron Leiblich, Richard Bell, Angus Campbell, Krishna Narahari, Hannah Wells, Daniel Chung, Clare Geere, Colette Clements, Kevin Pearse, Maggie Saunders, Ceri Morris, Hywel Thomas, Sashi Kommu, Ben Eddy, Jenny Hansen, Adrian Simoes, Curtis Phelan, Matthias Koslowski, Ian Morrison, Hide Yamamoto, Sukanya Ghosh, Alastair Henderson, Julia Sunnucks, Alison Richards, Iveta Los, Graham Russell, Ab A Bhat, Biswaranjan Datta, Dler Besarani, Amit Goel, Jenny Pablo, Soni Xavier, Ellen O’Grady, Bethany Jones, Altan Omer, Christopher Berridge, Davina Hewitt, Sian McKee, Subiatu Wurie, Bidisha Sinha, Nicholas Hedley, Tom A Leslie, Reema A Babu, Claire Chama-Hall, Hayley Moss, Jeannette Smith, Angus Molyneux, Khalid Enver, Imoh Ibiok, Sharadchandra Prasad, Robert HR Gray, Jessica Whitburn, Marjorie Castillo, Sonia Dayal, Yalda Alizadeh, Simon Bay, James WF Catto, Derek J Rosario, Amy Cooney, Michael Slater, Irene Sharkey, Susan Morgan, Steven Kennish, Daniel W Good, Katie Power, Rebecca O’Donnell, Sarah Myerscough, Marie O’Donnell, Julian Keanie, Matthew PC Liew, Joanna Borzomatoa, Lee Unsworth

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.